Market Closed -
Warsaw S.E.
11:55:42 2024-06-26 EDT
|
5-day change
|
1st Jan Change
|
0.252
PLN
|
+0.80%
|
|
-0.59%
|
-13.10%
|
Fiscal Period: December |
2016
|
2017
|
2018
|
2019
|
2020
|
2021
|
---|
Capitalization
1 |
102.2
|
41.48
|
37.97
|
30.84
|
96.39
|
42.65
|
Enterprise Value (EV)
1 |
104.3
|
30.06
|
33.06
|
29.57
|
102.7
|
50.93
|
P/E ratio
|
-43.8
x
|
71
x
|
-18.7
x
|
-22.7
x
|
-40.6
x
|
-6.05
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1,794
x
|
-
|
41.2
x
|
105
x
|
375
x
|
7,108
x
|
EV / Revenue
|
1,830
x
|
-
|
35.9
x
|
101
x
|
399
x
|
8,489
x
|
EV / EBITDA
|
-47.4
x
|
-7.09
x
|
-13.1
x
|
-21.4
x
|
-45.9
x
|
-3.15
x
|
EV / FCF
|
-3.63
x
|
2.51
x
|
-3.49
x
|
-27.1
x
|
-4.98
x
|
7.52
x
|
FCF Yield
|
-27.6%
|
39.9%
|
-28.6%
|
-3.68%
|
-20.1%
|
13.3%
|
Price to Book
|
4.21
x
|
1.64
x
|
1.12
x
|
0.94
x
|
3.14
x
|
1.78
x
|
Nbr of stocks (in thousands)
|
58,418
|
58,418
|
58,418
|
58,418
|
58,418
|
58,418
|
Reference price
2 |
1.750
|
0.7100
|
0.6500
|
0.5280
|
1.650
|
0.7300
|
Announcement Date
|
4/5/17
|
4/4/18
|
4/27/19
|
6/25/20
|
4/19/21
|
5/2/22
|
Fiscal Period: December |
2016
|
2017
|
2018
|
2019
|
2020
|
2021
|
---|
Net sales
1 |
0.057
|
-
|
0.921
|
0.294
|
0.257
|
0.006
|
EBITDA
1 |
-2.202
|
-4.24
|
-2.521
|
-1.383
|
-2.237
|
-16.15
|
EBIT
1 |
-2.32
|
-4.257
|
-2.538
|
-1.428
|
-2.247
|
-16.18
|
Operating Margin
|
-4,070.18%
|
-
|
-275.57%
|
-485.71%
|
-874.32%
|
-269,600%
|
Earnings before Tax (EBT)
1 |
-3.054
|
0.78
|
-1.995
|
-1.198
|
-1.986
|
-9.369
|
Net income
1 |
-2.016
|
0.635
|
-2.034
|
-1.361
|
-2.374
|
-7.044
|
Net margin
|
-3,536.84%
|
-
|
-220.85%
|
-462.93%
|
-923.74%
|
-117,400%
|
EPS
2 |
-0.0400
|
0.009999
|
-0.0348
|
-0.0233
|
-0.0406
|
-0.1206
|
Free Cash Flow
1 |
-28.78
|
11.99
|
-9.464
|
-1.089
|
-20.6
|
6.771
|
FCF margin
|
-50,487.72%
|
-
|
-1,027.52%
|
-370.54%
|
-8,013.91%
|
112,854.17%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
1,887.62%
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/5/17
|
4/4/18
|
4/27/19
|
6/25/20
|
4/19/21
|
5/2/22
|
Fiscal Period: December |
2016
|
2017
|
2018
|
2019
|
2020
|
2021
|
---|
Net Debt
1 |
2.09
|
-
|
-
|
-
|
6.26
|
8.29
|
Net Cash position
1 |
-
|
11.4
|
4.91
|
1.27
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-0.9482
x
|
-
|
-
|
-
|
-2.8
x
|
-0.5133
x
|
Free Cash Flow
1 |
-28.8
|
12
|
-9.46
|
-1.09
|
-20.6
|
6.77
|
ROE (net income / shareholders' equity)
|
-10.1%
|
2.56%
|
-6.87%
|
-4.07%
|
-7.48%
|
-25.8%
|
ROA (Net income/ Total Assets)
|
-5.6%
|
-9.26%
|
-4.28%
|
-2%
|
-2.95%
|
-21.1%
|
Assets
1 |
36.03
|
-6.859
|
47.54
|
68.18
|
80.51
|
33.44
|
Book Value Per Share
2 |
0.4200
|
0.4300
|
0.5800
|
0.5600
|
0.5200
|
0.4100
|
Cash Flow per Share
2 |
0.0100
|
0.0600
|
0.0200
|
0.0100
|
0.0400
|
0
|
Capex
1 |
0.05
|
0.03
|
0.01
|
0.04
|
0.01
|
-
|
Capex / Sales
|
94.74%
|
-
|
0.65%
|
12.59%
|
2.72%
|
-
|
Announcement Date
|
4/5/17
|
4/4/18
|
4/27/19
|
6/25/20
|
4/19/21
|
5/2/22
|
|
1st Jan change
|
Capi.
|
---|
| -13.10% | 4.52M | | -24.57% | 1B | | -16.26% | 134M | | -21.17% | 58.42M | | +0.41% | 57.74M |
Bio Medical Devices
|